Indian drug shares declined Wednesday following US President Trump’s tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India’s vital role in supplying affordable medicines to the US.
Can Nifty, Sensex extend gains after rallying up to 2% last week? 4 factors to watch on Monday
Indian benchmark indices Sensex and Nifty ended the week higher, gaining up to 0.5%, even as broader markets declined amid rising crude oil prices above
November 1, 2026